Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

A deal involving Kelonia could be reached as soon as Monday, with additional milestone-based payments reportedly included. The report suggests a constructive outcome for the company, though no transaction value or other terms were disclosed. Market impact should be limited unless more details emerge.

Analysis

A deal involving Kelonia could be reached as soon as Monday, with additional milestone-based payments reportedly included. The report suggests a constructive outcome for the company, though no transaction value or other terms were disclosed. Market impact should be limited unless more details emerge.